SCHEMBL5230152

SCHEMBL5230152

CSc1nc(Cl)c2c(n1)NCCN(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C2=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 9/20 0.37
JUN P05412 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35
NCSTN Q92542 2/20 0.35
APH1A Q96BI3 2/20 0.35
PSENEN Q9NZ42 2/20 0.35
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
EZH2 Q15910 1/20 0.32
TSHR P16473 1/20 0.32
CASP1 P29466 1/20 0.31
CASP5 P51878 1/20 0.31
USP2 O75604 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226634 0.95 TACR1 (0.38) TACR1JUNNFKB1NFKB2RELA
SCHEMBL14433988 0.86 TACR1 (0.36) TACR1JUNNFKB1NFKB2RELA
SCHEMBL5230109 0.82 TACR1 (0.39) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL14433957 0.82 TACR1 (0.37) TACR1JUNNFKB1NFKB2RELA
SCHEMBL5229260 0.81 TACR1 (0.41) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL5231611 0.80 TACR1 (0.39) TACR1JUNNFKB1NFKB2RELA
SCHEMBL5228468 0.80 TACR1 (0.41) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL5230402 0.79 TACR1 (0.40) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL5236630 0.77 TACR1 (0.37) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL13891758 0.71 TACR1 (0.41) TACR1JUNNFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496059-B1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES KYORIN SEIYAKU KK (JP) 2007-08-15 EP disclosed
US-7064119-B2 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 2006-06-20 US disclosed
US-20050159409-A1 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO. LTD. (JP) 2005-07-21 US disclosed
EP-1496059-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2005-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159409-A1 Fused bicyclic pyrimidine derivatives BDKRB1, BDKRB2, TACR1 TACR1 3/4885JUN 347/4885NFKB1 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.